Wellington Management Group LLP Purchases Shares of 23,759 Jasper Therapeutics, Inc. (NASDAQ:JSPR)

Wellington Management Group LLP acquired a new position in Jasper Therapeutics, Inc. (NASDAQ:JSPR) during the third quarter, Holdings Channel reports. The institutional investor acquired 23,759 shares of the company’s stock, valued at approximately $447,000.

Several other large investors have also made changes to their positions in JSPR. Samsara BioCapital LLC grew its holdings in Jasper Therapeutics by 11.4% in the 3rd quarter. Samsara BioCapital LLC now owns 584,642 shares of the company’s stock valued at $10,997,000 after buying an additional 59,642 shares during the last quarter. Braidwell LP acquired a new stake in shares of Jasper Therapeutics in the third quarter worth $9,091,000. Ally Bridge Group NY LLC increased its position in Jasper Therapeutics by 82.7% during the third quarter. Ally Bridge Group NY LLC now owns 399,466 shares of the company’s stock worth $7,514,000 after acquiring an additional 180,852 shares during the period. State Street Corp raised its stake in Jasper Therapeutics by 12.3% during the 3rd quarter. State Street Corp now owns 214,883 shares of the company’s stock valued at $4,042,000 after purchasing an additional 23,564 shares during the last quarter. Finally, Fernwood Investment Management LLC boosted its holdings in Jasper Therapeutics by 6.9% in the 3rd quarter. Fernwood Investment Management LLC now owns 52,897 shares of the company’s stock valued at $995,000 after purchasing an additional 3,427 shares during the period. Institutional investors and hedge funds own 79.85% of the company’s stock.

Jasper Therapeutics Price Performance

Shares of JSPR stock opened at $21.57 on Friday. The stock’s fifty day simple moving average is $21.50 and its 200 day simple moving average is $20.78. Jasper Therapeutics, Inc. has a one year low of $5.00 and a one year high of $31.01. The firm has a market cap of $323.57 million, a price-to-earnings ratio of -4.55 and a beta of 2.18.

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. HC Wainwright restated a “buy” rating and set a $65.00 price objective on shares of Jasper Therapeutics in a report on Thursday, October 24th. JMP Securities restated a “market outperform” rating and set a $70.00 price target on shares of Jasper Therapeutics in a research note on Tuesday, October 15th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Jasper Therapeutics in a research report on Monday, September 9th. BMO Capital Markets initiated coverage on Jasper Therapeutics in a research report on Friday, December 6th. They set an “outperform” rating and a $63.00 price objective on the stock. Finally, Evercore ISI reaffirmed an “outperform” rating and issued a $65.00 target price on shares of Jasper Therapeutics in a research report on Monday, August 26th. Ten analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and an average target price of $73.38.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.